Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
85 hedge funds and large institutions have $142M invested in Antares Pharma, Inc. in 2017 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 5 closing their positions.
360% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 5
186% more call options, than puts
Call options by funds: $372K | Put options by funds: $130K
85% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 13
20% more funds holding
Funds holding: 71 → 85 (+14)
18% more capital invested
Capital invested by funds: $121M → $142M (+$21.2M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.96M |
| 2 |
Millennium Management
New York
|
+$3.7M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$2.9M |
| 4 |
Morgan Stanley
New York
|
+$1.45M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$12.8M |
| 2 |
AC
Armistice Capital
New York
|
-$5.53M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.15M |
| 4 |
KCM
Kingdon Capital Management
New York
|
-$525K |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$434K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
76
Prelude Capital Management
New York
| $11K | +$9.62K | +4,000 | New |
|
|
SIM
77
Sonora Investment Management
Tucson,
Arizona
| $8.52K | – | – | – |
|
|
BTIS
78
BB&T Investment Services
Charlotte,
North Carolina
| $8K | – | – | – |
|
|
KF
79
Krilogy Financial
St. Louis,
Missouri
| $6K | – | – | – |
|
|
BWM
80
Baystate Wealth Management
Boston,
Massachusetts
| $4K | – | – | – |
|
|
CG
81
Cutler Group
San Francisco,
California
| $3K | – | – | – |
|
82
Fifth Third Bancorp
Cincinnati,
Ohio
| $3K | – | – | – |
|
|
AG
83
Advisor Group
Phoenix,
Arizona
| $1K | +$1.2K | +500 | New |
|
84
BNP Paribas Financial Markets
Paris,
France
| $82 | – | – | – |
|
85
Walleye Trading
New York
| $26 | +$21.6K | +9,000 | New |
|
|
86
Alyeska Investment Group
Chicago,
Illinois
| – | -$2.15M | -920,931 | Closed |
|
|
JHIU
87
Janus Henderson Investors US
Denver,
Colorado
| – | -$434K | -186,149 | Closed |
|
|
JGC
88
J. Goldman & Co
New York
| – | -$423K | -181,500 | Closed |
|
|
OAM
89
Oxford Asset Management
Oxford,
United Kingdom
| – | -$367K | -157,376 | Closed |
|
90
Group One Trading
Chicago,
Illinois
| – | -$722 | -300 | Closed |
|
ATRS Hedge Fund Activity: Q1 2017 in Review
85 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q1 2017, worth a combined $142M — up 18% from $121M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ATRS positions and 5 closed out — a net gain of 18 holders — while 24 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $6.96M. The largest seller was Broadfin Capital, cutting an estimated $12.8M.
- 85 institutional investors held Antares Pharma, Inc. (ATRS) as of Q1 2017, up from 71 in Q4 2016.
- Funds reported $142M of Antares Pharma, Inc. stock for Q1 2017, up 18% quarter-over-quarter.
- 23 funds opened new Antares Pharma, Inc. positions in Q1 2017 and 5 closed out, a net change of +18 holders.
- The largest Antares Pharma, Inc. buyer in Q1 2017 was BlackRock, an estimated $6.96M added.
- The largest Antares Pharma, Inc. seller in Q1 2017 was Broadfin Capital, an estimated $12.8M sold.
Based on aggregated 13F filings for Q1 2017.